Markets:

Overview

News

Currencies

International

Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

29.71 +4.87 (+19.61%)

Streaming Delayed Price Updated: 12:36 PM EST, Feb 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Celldex Therapeutics SVPs Engage In Heavy Transactions ↗

January 12, 2026

Multiple Senior Vice Presidents of this biotech company recently engaged in transactions that involved thousands of shares. What does this mean for the stock as it continues its long journey to regain...

Via The Motley Fool

Topics Regulatory Compliance

Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗

November 10, 2025

Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government...

Via Benzinga

Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics ↗

February 28, 2025

Via Benzinga

Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews ↗

January 29, 2025

Via Benzinga

What Analysts Are Saying About Celldex Therapeutics Stock ↗

December 20, 2024

Via Benzinga

Analyst Expectations For Celldex Therapeutics's Future ↗

October 13, 2025

Via Benzinga

Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) ↗

October 03, 2025

CLDX stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout above the $26.20 resistance level.

Via Chartmill

5 Analysts Assess Celldex Therapeutics: What You Need To Know ↗

September 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 08, 2025

Via Benzinga

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short ↗

August 20, 2025

Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom improvement.

Via Benzinga

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock ↗

November 20, 2024

Via Benzinga

What Analysts Are Saying About Celldex Therapeutics Stock ↗

August 20, 2025

Via Benzinga

La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

August 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 20, 2025

Via Benzinga

Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗

August 20, 2025

Via Benzinga

Why Are Celldex Shares Tumbling After Hours? ↗

August 19, 2025

The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit.

Via Stocktwits

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 19, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

August 19, 2025

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

August 13, 2025

Via Benzinga

Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress ↗

August 07, 2025

Celldex Therapeutics Q2 2025 earnings: Revenue misses estimates at $730K, but EPS beats at -$0.85. Strong cash position supports pipeline, with key barzolvolimab trials progressing.

Via Chartmill

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded ↗

June 15, 2025

Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks.

Via Stocktwits

Crude Oil Rises 6%; US Consumer Sentiment Surges In June ↗

June 13, 2025

Via Benzinga

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday ↗

June 13, 2025

Via Benzinga

Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics ↗

June 13, 2025

Via Benzinga

Analyst Expectations For Celldex Therapeutics's Future ↗

April 28, 2025

Via Benzinga

This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

April 28, 2025

Via Benzinga

7 Analysts Have This To Say About Celldex Therapeutics ↗

March 20, 2025

Via Benzinga

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

March 20, 2025

Via Benzinga

Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

February 18, 2025

Via Benzinga

Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors ↗

January 08, 2025

Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.